Incannex Healthcare Inc.

IXHL

US45333F1093

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-30 pm EDT			5-day change	1st Jan Change
2.89 ^USD	+14.68%		+26.75%	-37.72%

Mar. 05	Incannex Healthcare Inc. Announces CFO Changes	CI
Mar. 05	Incannex Healthcare Inc. Announces Executive Changes	CI

Incannex Healthcare Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023

February 14, 2024 at 06:17 am EST

Incannex Healthcare Inc. reported earnings results for the second quarter and six months ended December 31, 2023. For the second quarter, the company reported net loss was USD 5.24 million compared to USD 2.92 million a year ago. Basic loss per share from continuing operations was USD 0.33.
For the six months, net loss was USD 5.97 million compared to USD 41.07 million a year ago. Basic loss per share from continuing operations was USD 0.38 compared to USD 2.76 a year ago.

Latest news about Incannex Healthcare Inc.

Incannex Healthcare Inc. Announces CFO Changes	Mar. 05	CI
Incannex Healthcare Inc. Announces Executive Changes	Mar. 05	CI
Incannex Announces Positive Topline Results from Phase 2 Psi-GAD1 Clinical Trial of Psilocybin in Generalised Anxiety Disorder	Feb. 28	CI
Incannex Healthcare Completes Pre-Investigational New Drug Meeting on CannQuit-N With US FDA	Feb. 16	MT
Incannex Healthcare Inc. Completes Successful Pre-IND Meeting with the FDA for CannQuit-N	Feb. 16	CI
Incannex Healthcare Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	Feb. 14	CI
Incannex Commences Dosing in Phase 2 Clinical Trial Assessing IHL-675A in Patients with Rheumatoid Arthritis	Jan. 24	CI
Incannex Completes Dosing and Therapy in Phase 2 ?Psigad? Clinical Trial Assessing Psilocybin-Assisted Psychotherapy for Generalized Anxiety Disorder	Jan. 18	CI
Incannex Healthcare Gets Institutional Review Board Approval For IHL-42X Drug Trial	Jan. 17	MT
Incannex Healthcare Inc. Receives IRB Approval for the Reposa Phase 2/3 Clinical Trial Protocol to Assess IHL-42X Drug in Patients with Obstructive Sleep Apnea	Jan. 17	CI
Incannex Healthcare Ltd. Receives Ethics Board Endorsement for Psychedelic Assisted Therapy At Its First Clinic Based in Melbourne, Australia	Dec. 21	CI
Incannex Healthcare Inc Update on Ihl-42X Drug Candidate in Phase 2/3 Clinical Trial in Obstructive Sleep Apnea	Dec. 06	CI
Incannex Healthcare Inc. Reports Earnings Results for the Full Year Ended June 30, 2023	23-08-30	CI
Incannex Healthcare Inc. Reports Earnings Results for the Half Year Ended December 31, 2022	23-02-26	CI

Chart Incannex Healthcare Inc.

Duration

Period

More charts

Company Profile

Incannex Healthcare Inc. is a clinical-stage pharmaceutical development company. The Company is developing medicinal cannabinoid pharmaceutical products and psychedelic medicine therapies for the treatment of obstructive sleep apnea (OSA), traumatic brain injury (TBI) and concussion, lung inflammation (ARDS, COPD, asthma, bronchitis), rheumatoid arthritis, inflammatory bowel disease, anxiety disorders, addiction disorders, and pain, among other indications. The Companyâs diversified portfolio includes 28 distinct research and development (R&D) programs, and six clinical trials underway. Its clinical projects include IHL-42X Obstructive Sleep Apnea, IHL-675A Inflammatory Lung Disease, IHL-675A Rheumatoid Arthritis, IHL-675A Inflammatory Bowel Disease, IHL-216A Concussion and TBI, PSI-GAD Psilocybin for anxiety, MedChew GB Post-herpatic Neuralgia and MedChew -1401 Pain and Spasticity in Multiple Sclerosis.

Sector

Pharmaceuticals

Calendar

2024-08-27 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Annual profits - Rate of surprise

Company calendar

Sector Alternative Medicine

	1st Jan change	Capi.
INCANNEX HEALTHCARE INC.	-37.72%	40M
DONG-E-E-JIAO CO.,LTD.	+39.33%	6.01B
SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD.	-18.38%	4.4B
TASLY PHARMACEUTICAL GROUP CO., LTD	-9.17%	3.17B
TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED	+3.98%	3.07B
SHANDONG BUCHANG PHARMACEUTICALS CO., LTD.	-3.41%	2.51B
HENAN LINGRUI PHARMACEUTICAL CO., LTD.	+48.74%	1.88B
GUANGYUYUAN CHINESE HERBAL MEDICINE CO., LTD.	-4.82%	1.73B
TIBET CHEEZHENG TIBETAN MEDICINE CO., LTD.	-1.24%	1.65B
TIANJIN CHASE SUN PHARMACEUTICAL CO.,LTD	-8.96%	1.58B

Alternative Medicine